| Name | PAR-4 Agonist Peptide, amide TFA |
| Description | PAR-4 Agonist Peptide, amide TFA (PAR-4-AP (TFA)), is a selective activator of the proteinase-activated receptor-4 (PAR-4) that does not affect PAR-1 or PAR-2, and its activity can be inhibited by a PAR-4 antagonist. |
| In vivo | SCID mice demonstrate a markedly enhanced abdominal response to colorectal distension (CRD), with distension levels ranging from 0.04 to 0.1 mL amplifying the intensity of the EMG response from 384% to 132%, respectively, as compared to BALB/cBy controls (P<0.01; P<0.01; P<0.01; P<0.001). Activation of PAR-4 significantly mitigates this hypersensitivity (P<0.01, P<0.05; P<0.05; P<0.05)[1]. |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 100 mg/mL (125.81 mM), Sonication is recommended.
DMSO : 250 mg/mL (314.54 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (6.29 mM), Sonication is recommended.
|
| Keywords | Thrombin receptors | ProteaseactivatedReceptor | Protease-Activated Receptor (PAR) | Proteaseactivated Receptor | Protease Activated Receptor (PAR) | PAR-4-AP | PAR-4 Agonist Peptide, amide TFA | PAR4 Agonist Peptide, amide TFA | PAR-4 Agonist Peptide, amide | PAR-4 | PAR 4 Agonist Peptide, amide TFA | Inhibitor | inhibit | AY-NH2 |
| Inhibitors Related | FSLLRY-NH2 TFA(245329-02-6 free base) | LRGILS-NH2 acetate | Protease-Activated Receptor-1, PAR-1 Agonist acetate | PAR-2 Activating Peptide acetate | ML-354 | Atopaxar | Vorapaxar sulfate | Trypsin | Vorapaxar | AY 77 | PAR-2-IN-1 | VKGILS-NH2 Acetate |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Peptide Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library |
United States
